INDGN

Indegene Share Price

₹641.90 +6.5 (1.02%)

21 Nov, 2024 14:26

SIP TrendupStart SIP in INDGN

Start SIP

Performance

  • Low
  • ₹627
  • High
  • ₹645
  • 52 Week Low
  • ₹470
  • 52 Week High
  • ₹736
  • Open Price₹639
  • Previous Close₹635
  • Volume262,511

Investment Returns

  • Over 1 Month -8.29%
  • Over 3 Month + 9.9%
  • Over 6 Month + 15.42%
  • Over 1 Year + 42.01%
SIP Lightning

Smart Investing Starts Here Start SIP with Indegene for Steady Growth!

Invest Now

Indegene Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 15,359
  • P/B Ratio
  • 10.7
  • Average True Range
  • 30.19
  • EPS
  • 15.52
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.92
  • RSI
  • 43.3
  • MFI
  • 56.18

Indegene Financials

Indegene Technicals

EMA & SMA

Current Price
₹641.90
+ 6.5 (1.02%)
pointer
  • stock-down_img
  • Bullish Moving Average 2
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹662.00
  • 50 Day
  • ₹655.64
  • 100 Day
  • ₹624.62
  • 200 Day
  • -

Resistance and Support

644.08 Pivot Speed
  • R3 689.47
  • R2 677.23
  • R1 656.32
  • S1 623.17
  • S2 610.93
  • S3 590.02

What's your outlook on Indegene?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Indegene is a global healthcare solutions company providing commercial, medical, and digital transformation services to life sciences companies. It helps pharmaceutical, biotech, and healthcare organizations enhance patient outcomes through data-driven strategies and innovative technology solutions.

Indegene Ltd has an operating revenue of Rs. 2,643.80 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 18% is great, ROE of 23% is exceptional. The company has a reasonable debt to equity of 23%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 59 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 85 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Indegene Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-28 Quarterly Results
2024-08-01 Quarterly Results
2024-05-29 Audited Results

Indegene F&O

Indegene Shareholding Pattern

0%
1.64%
0.11%
4.82%
0.02%
24.32%
69.09%

About Indegene

  • NSE Symbol
  • INDGN
  • BSE Symbol
  • 544172
  • ISIN
  • INE065X01017

Similar Stocks to Indegene

Indegene FAQs

Indegene share price is ₹641 As on 21 November, 2024 | 14:12

The Market Cap of Indegene is ₹15358.7 Cr As on 21 November, 2024 | 14:12

The P/E ratio of Indegene is As on 21 November, 2024 | 14:12

The PB ratio of Indegene is 10.7 As on 21 November, 2024 | 14:12

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23